How are XENE long call max profit and max loss calculated?

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the XENE long call priced from the end-of-day chain at a 30-day expiry (ATM IV 42.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$410.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a XENE long call?

The breakeven for the XENE long call priced on this page is roughly $59.10 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current XENE market-implied 1-standard-deviation expected move is approximately 12.30%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current XENE implied volatility affect this long call?

XENE ATM IV is at 42.90% with IV rank near 5.83%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

XENE Long Call Strategy

XENE (Xenon Pharmaceuticals Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

XENE (Xenon Pharmaceuticals Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $4.41B, a beta of 0.65 versus the broader market, a 52-week range of 28.19-63.95, average daily share volume of 1.4M, a public-listing history dating back to 2014, approximately 316 full-time employees. These structural characteristics shape how XENE stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.65 indicates XENE has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a long call on XENE?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

Current XENE snapshot

As of May 15, 2026, spot at $54.39, ATM IV 42.90%, IV rank 5.83%, expected move 12.30%. The long call on XENE below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 63-day expiry.

Why this long call structure on XENE specifically: XENE IV at 42.90% is on the cheap side of its 1-year range, which favors premium-buying structures like a XENE long call, with a market-implied 1-standard-deviation move of approximately 12.30% (roughly $6.69 on the underlying). The 63-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated XENE expiries trade a higher absolute premium for lower per-day decay. Position sizing on XENE should anchor to the underlying notional of $54.39 per share and to the trader's directional view on XENE stock.

XENE long call setup

The XENE long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With XENE near $54.39, the first option leg uses a $55.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed XENE chain at a 63-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 XENE shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$55.00	$4.10

XENE long call risk and reward

Net Premium / Debit: -$410.00
Max Profit (per contract): Unbounded
Max Loss (per contract): -$410.00
Breakeven(s): $59.10
Risk / Reward Ratio: Unbounded

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

XENE long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on XENE. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	-$410.00
$12.03	-77.9%	-$410.00
$24.06	-55.8%	-$410.00
$36.08	-33.7%	-$410.00
$48.11	-11.5%	-$410.00
$60.13	+10.6%	+$103.41
$72.16	+32.7%	+$1,305.89
$84.18	+54.8%	+$2,508.38
$96.21	+76.9%	+$3,710.86
$108.23	+99.0%	+$4,913.34

When traders use long call on XENE

Long calls on XENE express a bullish thesis with defined risk; traders use them ahead of XENE catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

XENE thesis for this long call

The market-implied 1-standard-deviation range for XENE extends from approximately $47.70 on the downside to $61.08 on the upside. A XENE long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current XENE IV rank near 5.83% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on XENE at 42.90%. As a Healthcare name, XENE options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to XENE-specific events.

XENE long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. XENE positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move XENE alongside the broader basket even when XENE-specific fundamentals are unchanged. Long-premium structures like a long call on XENE are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current XENE chain quotes before placing a trade.

Frequently asked questions

What is a long call on XENE?: A long call on XENE is the long call strategy applied to XENE (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With XENE stock trading near $54.39, the strikes shown on this page are snapped to the nearest listed XENE chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are XENE long call max profit and max loss calculated?: Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the XENE long call priced from the end-of-day chain at a 30-day expiry (ATM IV 42.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$410.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a XENE long call?: The breakeven for the XENE long call priced on this page is roughly $59.10 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current XENE market-implied 1-standard-deviation expected move is approximately 12.30%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on XENE?: Long calls on XENE express a bullish thesis with defined risk; traders use them ahead of XENE catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current XENE implied volatility affect this long call?: XENE ATM IV is at 42.90% with IV rank near 5.83%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.